BioCryst Pharmaceuticals (BCRX) said Monday a study of berotralstat, which it markets under the brand name of Orladeyo, showed a significant reduction in hospitalizations, emergency room visits, and use of on-demand therapies for patients with hereditary angioedema in the US.
The company said that the study of berotralstat will be presented at the Academy of Managed Care Pharmacy Nexus 2024 national meeting being held in Las Vegas, Nevada, this week.
Price: 7.59, Change: +0.16, Percent Change: +2.15
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。